Business Context and Reporting Period
This Form 8-K filing by Bio-Rad Laboratories, Inc. (NYSE: BIO) was submitted on December 4, 2013, with a report date of December 10, 2013. The filing primarily addresses corporate governance changes, specifically the appointment of a new director to the Board of Directors.
Key Financial Metrics
This filing does not contain current period financial results, revenue, profit, cash flow, or debt metrics. The only financial data provided is historical context within the press release, noting that the company had revenues exceeding $2 billion in 2012. The filing discloses that the new director will receive an annual fee of $85,000 plus travel expense reimbursement.
Material Changes
The material change reported is the appointment of Robert M. Malchione to the Board of Directors, effective January 1, 2014. Mr. Malchione is scheduled to stand for election at the annual meeting of stockholders in April 2014. There are no reported changes to financial operations or executive management other than this board appointment.
Guidance, Outlook, and Risks
The filing includes standard forward-looking statement disclaimers regarding risks and uncertainties that could cause actual results to vary. It references the "Risk Factors" in the company's most recent Form 10-K and 10-Q filings for detailed risk information. No specific financial guidance or outlook for future periods is provided in this document.
Investor Verification Checklist
- Verify the effective date of Robert M. Malchione's board appointment (January 1, 2014).
- Confirm the date of the upcoming annual meeting of stockholders (April 22, 2014) where Mr. Malchione will stand for election.
- Review the company's most recent Form 10-K for detailed risk factors and the 2012 revenue figure cited as exceeding $2 billion.
- Check for any subsequent filings regarding the outcome of the director election in April 2014.